See the DrugPatentWatch profile for Sevelamer
Sevelamer carbonate is a medication used to treat hyperphosphatemia, a condition characterized by high levels of phosphate in the blood. It works by binding to phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [1].
How does sevelamer carbonate work in the body?
Sevelamer carbonate is an anion-exchange resin. When taken orally, it does not absorb into the bloodstream. Instead, it acts within the digestive system. The positively charged molecules of sevelamer bind to negatively charged phosphate ions in the gut. This binding prevents the phosphate from being absorbed by the intestinal wall and subsequently entering the circulation. The bound phosphate is then eliminated from the body through feces [1].
What conditions is sevelamer carbonate prescribed for?
This medication is primarily prescribed for patients with chronic kidney disease (CKD) on dialysis who have elevated phosphate levels [1]. Hyperphosphatemia is a common complication in individuals with impaired kidney function because the kidneys are unable to effectively filter excess phosphate from the blood.
What are the potential side effects of sevelamer carbonate?
Common side effects associated with sevelamer carbonate include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain. Less common side effects may involve rash, itching, and muscle pain. It can also interfere with the absorption of fat-soluble vitamins (A, D, E, and K) and folic acid, so supplementation may be recommended [1].
How does sevelamer carbonate compare to other phosphate binders?
Sevelamer carbonate belongs to a class of drugs known as non-calcium-based phosphate binders. Other phosphate binders include calcium-based binders (like calcium acetate and calcium carbonate) and other non-calcium-based binders (like lanthanum carbonate and ferric compounds). Non-calcium-based binders are often preferred in certain patients to avoid the risk of calcium overload, which can lead to vascular calcification and cardiovascular complications [2].
When does sevelamer carbonate patent protection end?
Information regarding the specific patent expiry dates for sevelamer carbonate can be found on DrugPatentWatch.com [3]. Patent expiration is crucial as it typically allows for the potential market entry of generic versions of the drug, which can lead to lower prices.
Who manufactures sevelamer carbonate?
The originator brand for sevelamer carbonate is Renagel, which was developed by Genzyme (a Sanofi company). However, generic versions of sevelamer carbonate are now available from various pharmaceutical manufacturers [4].